<?xml version="1.0" encoding="UTF-8"?>
<p>Only 5 of the 45 eligible patients in the present study did not complete induction chemotherapy (R‐High CHOP/CHASER) because of toxicity (N = 3), disease progression (N = 1), or refusal (N = 1). These proportions were much lower than the reported 29% of patients who did not complete the planned 6 or 8 HyperCVAD/MA cycles,
 <xref rid="cas13719-bib-0023" ref-type="ref">23</xref> and the reported 63% of patients who did not complete the planned 4 HyperCVAD/MA cycles with 3 deaths during therapy in a phase II study by Gruppo Italiano Studio Linfomi,
 <xref rid="cas13719-bib-0024" ref-type="ref">24</xref> but was comparable to the 3% of such patients reported in the Nordic MCL‐2 study
 <xref rid="cas13719-bib-0008" ref-type="ref">8</xref> and the 6.7% of such patients reported in the GELA study.
 <xref rid="cas13719-bib-0009" ref-type="ref">9</xref>
</p>
